Researchers Point to IL-26 as Biomarker of Severe COVID-19 – AJMC.com Managed Markets Network

by | Nov 18, 2022 | COVID-19

High levels of interleukin (IL)-26 levels correlate with an exaggerated inflammatory response that signifies severe cases of the disease, according to researchers.A study published by researchers in Sweden indicates that systemic interleukin (IL)-26 is a possible biomarker of severe COVID-19.The findings were published in Frontiers in Immunology.According to the authors at Sweden’s Karolinska Institutet, high IL-26 levels correlate with an exaggerated inflammatory response that signifies severe cases of the disease.IL-26 has antiviral and antibacterial effects and mobilizes immune cells to fight bacterial infections in the lungs as well as chronic respiratory disease.However, the researchers said they conducted the study because the role of IL-26 in COVID-19 has not been thoroughly investigated. There is also a need to know more about these underlying immunological mechanisms in order to find better treatments as well as improved diagnostics.To conduct the study, researchers recruited 49 patients who had been hospitalized with SARS-CoV-2-infection, 44 of whom had severe symptoms and needed oxygen therapy. The patients were recruited at a hospital in Stockholm from June 2020 to January 2021. A control group of 27 healthy individuals was also recruited during the same period. The researchers then measured levels of IL-26 protein and other inflammatory compounds in the blood.AdvertisementThe concentration of IL-26 correlates with those of the neutrophil-mobilizing cytokines IL-8 and TNFα, the authors said. Healthy controls had much lower levels of IL-26.In addition, “the …

Article Attribution | Read More at Article Source

Share This